DBV Technologies Announces Filing of 2025 Annual Report on Form 10-K and Universal Registration Document
Châtillon, France, March 26, 2026
DBV Technologies Announces Filing of 2025 Annual Report on Form 10-K and Universal Registration Document
DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a late-stage biopharmaceutical company (the “Company”), today announced the filing, for the year ended December 31, 2025, of its Annual Report on Form 10-K with the U.S. Securities and Exchange Commission (“SEC”) and its Universal Registration Document (“ 2025 URD”) with the French market authority, “Autorité des Marchés Financiers” (“AMF”).
In compliance with French law, the following information are included in the 2025 URD :
- The 2025 annual financial report;
- The Board of Directors’ corporate governance report (“rapport sur le gouvernement d’entreprise”) required under Article L. 225-37 of the French Commercial Code;
- The description of the share buy-back program;
- The statutory auditor reports;
- The information regarding the statutory auditor fees.
These documents can be accessed on the Regulated Information section of the Company 's website at www.dbv-technologies.com. In addition, the Form 10-K is available on the SEC’s website at www.sec.gov and the 2025 URD on the AMF’s website at www.amf-france.org.
About DBV Technologies
DBV Technologies is a late-stage biopharmaceutical company developing treatment options for food allergies and other immunologic conditions with significant unmet medical need. DBV Technologies is currently focused on investigating the use of its proprietary VIASKIN® patch technology to address food allergies, which are caused by a hypersensitive immune reaction and characterized by a range of symptoms varying in severity from mild to life-threatening anaphylaxis. Millions of people live with food allergies, including young children.
Through epicutaneous immunotherapy (EPIT), the VIASKIN® Patch is designed to
introduce microgram amounts of a biologically active compound to the immune system through intact skin. EPIT is a new class of non-invasive treatment that seeks
to modify an individual’s underlying allergy by re-educating the immune system to
become desensitized to allergen by leveraging the skin’s immune tolerizing properties. DBV Technologies is committed to transforming the care of food allergic
people. The Company’s food allergy programs include ongoing clinical trials of the
VIASKIN® Peanut Patch in peanut allergic toddlers (1 through 3 years of age) and
children (4 through 7 years of age).
DBV Technologies is headquartered in Châtillon, France, with North American
operations in Warren, NJ. The Company’s ordinary shares are traded on segment B
of Euronext Paris (DBV, ISIN code: FR0010417345) and the Company’s ADSs (each
representing five ordinary shares) are traded on the Nasdaq Capital Market (DBVT – CUSIP: 23306J309).
For more information, please visit www.dbvtechnologies.com and engage with us on X (formerly Twitter) and LinkedIn.
Investor Contact
Jonathan Neely
DBV Technologies
Jonathan.neely@dbv-technologies.com
Media Contact
Brett Whelan
DBV Technologies
Brett.whelan@dbv-technologies.com
Attachment
© 2026 GlobeNewswire, Inc. All Rights Reserved.
